{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:24:32Z","timestamp":1783488272330,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11102-022-01238-8","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T09:02:36Z","timestamp":1654592556000},"page":"722-725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pituitary acting drugs: cabergoline and pasireotide"],"prefix":"10.1007","volume":"25","author":[{"given":"M\u00f4nica R.","family":"Gadelha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Eduardo","family":"Wildemberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"1238_CR1","doi-asserted-by":"crossref","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, Boguszewski CL, Bronstein MD, Buchfelder M, Carmichael JD, Casanueva FF, Castinetti F, Chanson P, Findling J, Gadelha M, Geer EB, Giustina A, Grossman A, Gurnell M, Ho K, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Kelly DF, Lacroix A, McCormack A, Melmed S, Molitch M, Mortini P, Newell-Price J, Nieman L, Pereira AM, Petersenn S, Pivonello R, Raff H, Reincke M, Salvatori R, Scaroni C, Shimon I, Stratakis CA, Swearingen B, Tabarin A, Takahashi Y, Theodoropoulou M, Tsagarakis S, Valassi E, Varlamov EV, Vila G, Wass J, Webb SM, Zatelli MC, Biller (2021) B.M.K.: Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9, 847\u2013875","DOI":"10.1016\/S2213-8587(21)00235-7"},{"key":"1238_CR2","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40618-020-01335-0","volume":"43","author":"F Gatto","year":"2020","unstructured":"Gatto F, Arvigo M, Ferone D (2020) Somatostatin receptor expression and patients\u2019 response to targeted medical treatment in pituitary tumors: evidences and controversies. J Endocrinol Invest 43:1543\u20131553","journal-title":"J Endocrinol Invest"},{"key":"1238_CR3","doi-asserted-by":"publisher","unstructured":"Pivonello R, Pivonello C, Simeoli C, De Martino MC, Colao A (2022) The dopaminergic control of Cushing\u2019s syndrome. J Endocrinol Invest. doi: https:\/\/doi.org\/10.1007\/s40618-021-01661-x","DOI":"10.1007\/s40618-021-01661-x"},{"key":"1238_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1530\/EJE-16-0662","volume":"176","author":"A Ferriere","year":"2017","unstructured":"Ferriere A, Cortet C, Chanson P, Delemer B, Caron P, Chabre O, Reznik Y, Bertherat J, Rohmer V, Briet C, Raingeard I, Castinetti F, Beckers A, Vroonen L, Maiter D, Cephise-Velayoudom FL, Nunes ML, Haissaguerre M, Tabarin A (2017) Cabergoline for Cushing\u2019s disease: a large retrospective multicenter study. Eur J Endocrinol 176:305\u2013314","journal-title":"Eur J Endocrinol"},{"key":"1238_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1210\/jc.2008-1533","volume":"94","author":"R Pivonello","year":"2009","unstructured":"Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SW, Colao A (2009) The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94:223\u2013230","journal-title":"J Clin Endocrinol Metab"},{"key":"1238_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1530\/EJE-10-0382","volume":"163","author":"A Godbout","year":"2010","unstructured":"Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A (2010) Cabergoline monotherapy in the long-term treatment of Cushing\u2019s disease. Eur J Endocrinol 163:709\u2013716","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"1238_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11102-011-0309-0","volume":"15","author":"MP Manavela","year":"2012","unstructured":"Manavela MP, Danilowicz K, Bruno OD (2012) Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report. Pituitary 15(Suppl 1):33\u201336","journal-title":"Pituitary"},{"key":"1238_CR8","first-page":"300","volume":"62","author":"LA Casulari","year":"2004","unstructured":"Casulari LA, Naves LA, Mello PA, Pereira Neto A, Papadia C (2004) Nelson\u2019s syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 62:300\u2013305","journal-title":"Horm Res"},{"key":"1238_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM, Group PBS (2012) A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 366:914\u2013924","journal-title":"N Engl J Med"},{"key":"1238_CR10","first-page":"17","volume":"6","author":"A Lacroix","year":"2018","unstructured":"Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, Boscaro M, Salvatori R, Yamada M, Tauchmanova L, Roughton M, Ravichandran S, Petersenn S, Biller BMK, Newell-Price J, Group PGS (2018) Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial. The lancet. Diabetes & endocrinology 6:17\u201326","journal-title":"Diabetes & endocrinology"},{"key":"1238_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11102-019-01021-2","volume":"23","author":"A Lacroix","year":"2020","unstructured":"Lacroix A, Gu F, Schopohl J, Kandra A, Pedroncelli AM, Jin L, Pivonello R (2020) Pasireotide treatment significantly reduces tumor volume in patients with Cushing\u2019s disease: results from a Phase 3 study. Pituitary 23:203\u2013211","journal-title":"Pituitary"},{"key":"1238_CR12","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s11102-012-0427-3","volume":"15","author":"I Shimon","year":"2012","unstructured":"Shimon I, Rot L, Inbar E (2012) Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review. Pituitary 15:608\u2013613","journal-title":"Pituitary"},{"key":"1238_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cen.12431","volume":"81","author":"R Pivonello","year":"2014","unstructured":"Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM, Group PBS (2014) Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing\u2019s disease: results from a Phase III study. Clin Endocrinol (Oxf) 81:408\u2013417","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1238_CR14","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s40618-020-01246-0","volume":"43","author":"A Lacroix","year":"2020","unstructured":"Lacroix A, Bronstein MD, Schopohl J, Delibasi T, Salvatori R, Li Y, Barkan A, Suzaki N, Tauchmanova L, Ortmann CE, Ravichandran S, Petersenn S, Pivonello R (2020) Long-acting pasireotide improves clinical signs and quality of life in Cushing\u2019s disease: results from a phase III study. J Endocrinol Invest 43:1613\u20131622","journal-title":"J Endocrinol Invest"},{"key":"1238_CR15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12020-017-1316-3","volume":"57","author":"S Petersenn","year":"2017","unstructured":"Petersenn S, Salgado LR, Schopohl J, Portocarrero-Ortiz L, Arnaldi G, Lacroix A, Scaroni C, Ravichandran S, Kandra A, Biller BMK (2017) Long-term treatment of Cushing\u2019s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. Endocrine 57:156\u2013165","journal-title":"Endocrine"},{"key":"1238_CR16","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/cen.14081","volume":"91","author":"M Fleseriu","year":"2019","unstructured":"Fleseriu M, Petersenn S, Biller BMK, Kadioglu P, De Block C, T\u2019Sjoen G, Vantyghem MC, Tauchmanova L, Wojna J, Roughton M, Lacroix A, Newell-Price J (2019) Long-term efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: A Phase III extension study. Clin Endocrinol (Oxf) 91:776\u2013785","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1238_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1530\/EJE-15-0689","volume":"174","author":"K Hayashi","year":"2016","unstructured":"Hayashi K, Inoshita N, Kawaguchi K, Ibrahim Ardisasmita A, Suzuki H, Fukuhara N, Okada M, Nishioka H, Takeuchi Y, Komada M, Takeshita A, Yamada S (2016) The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing\u2019s disease. Eur J Endocrinol 174:213\u2013226","journal-title":"Eur J Endocrinol"},{"key":"1238_CR18","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/cen.13940","volume":"90","author":"R Steeds","year":"2019","unstructured":"Steeds R, Stiles C, Sharma V, Chambers J, Lloyd G, Drake W (2019) Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: A joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Clin Endocrinol (Oxf) 90:662\u2013669","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1238_CR19","doi-asserted-by":"publisher","first-page":"579606","DOI":"10.3389\/fendo.2020.579606","volume":"11","author":"JM Hinojosa-Amaya","year":"2020","unstructured":"Hinojosa-Amaya JM, Johnson N, Gonz\u00e1lez-Torres C, Varlamov EV, Yedinak CG, McCartney S, Fleseriu M (2020) Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas. Front Endocrinol (Lausanne) 11:579606","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1238_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11102-013-0483-3","volume":"17","author":"A Colao","year":"2014","unstructured":"Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF (2014) Managing hyperglycemia in patients with Cushing\u2019s disease treated with pasireotide: medical expert recommendations. Pituitary 17:180\u2013186","journal-title":"Pituitary"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01238-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-022-01238-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01238-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T09:24:32Z","timestamp":1666430672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-022-01238-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1238"],"URL":"https:\/\/doi.org\/10.1007\/s11102-022-01238-8","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"21 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MRG has received speaker fees from Recordati Rare Diseases, attended Recordati Rare Diseases advisory boards, and is principal investigator in clinical trials from Recordati Rare Diseases and Novartis. LEW has received speaker fees from Novartis and participates as a sub-investigator in Recordati Rare Diseases and Novartis clinical trials. IS has received speaker fees from Novartis and Medison, attended Novartis advisory board, and participated as an investigator in Novartis and Strongbridge Pharma clinical trials.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}